Analyst Edward White of H.C. Wainwright reiterated a Buy rating on Inozyme Pharma (INZY – Research Report), retaining the price target of $16.00.
Edward White’s rating is based on the promising potential of Inozyme Pharma’s INZ-701 as a treatment for ENPP1 Deficiency, a rare genetic disorder with no currently approved therapies. The publication of real-world data highlights the severity of this condition and underscores the high unmet medical need, suggesting that INZ-701 could fill a critical gap in treatment options.
Furthermore, the company’s ongoing ENERGY-3 study, which evaluates the efficacy and safety of INZ-701, has shown positive interim results, bolstering confidence in its potential success. The study’s design and endpoints have been agreed upon with regulatory bodies, enhancing the credibility of its outcomes. Edward White’s Buy rating is also supported by projected revenue growth and a strategic focus on regulatory approval, with anticipated sales and market launch in 2027.
In another report released on April 8, Needham also maintained a Buy rating on the stock with a $15.00 price target.